Senseonics (Nasdaq:SENS) announced new data from a real-world study demonstrating the sustained performance of its Eversense 365 CGM.
Afon Technology says that its Glucowear non-invasive continuous glucose monitor (CGM) demonstrated significant accuracy in its first trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results